drugset
Drugs / autologous peripheral blood mesenchymal stem cell
last change Dec 2023 re-read 3 minutes ago

autologous peripheral blood mesenchymal stem cell

Cell therapy

Developed for
articular cartilage disorder
Investigated by
Hebei Medical University Third Hospital · Inner Mongolia People's Hospital · Peking University Third Hospital · Tianjin Hospital

Trials 1

today NCT04953572 · Ph 1
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04953572 Aug 2021 → Dec 2023 articular cartilage disorder Peking University Third Hospital Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as autologous peripheral blood mesenchymal stem cell ClinicalTrials.gov intervention name — accepted as the source's own label NCT04953572 ↗
Modality Cell therapy “autologous peripheral blood mesenchymal stem cell therapy” NCT04953572 ↗